John F. Forbes
University of Limerick
373 Papers
2.2K Citations
John F. Forbes is an academic researcher from University of Limerick. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 88, co-authored 368 publications. Previous affiliations of John F. Forbes include University of Newcastle & University of Melbourne.
Chat about Author
Papers
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Mitch Dowsett,Jack Cuzick,Jim Ingle,Alan S. Coates,John F. Forbes,Judith M Bliss,Marc Buyse,Michael J. Baum,Aman U. Buzdar,Marco Colleoni,Charles Coombes,Claire Snowdon,Michael Gnant,Raimund Jakesz,Manfred Kaufmann,Francesco Boccardo,Jon Godwin,C Davies,Richard Peto +18 more
TL;DR: There was no convincing heterogeneity in the proportional recurrence reduction with respect to age, nodal status, tumor grade, or progesterone receptor status and no indication of an increase in nonbreast deaths with AIs in either cohort.
803
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
Jack Cuzick,John F. Forbes,Rhiannon Tudor Edwards,Michael J. Baum,Simon Cawthorn,Alan S. Coates,A Hamed,A Howell,Thomas Powles +8 more
TL;DR: Prophylactic use of tamoxifen is contraindicated in women at high risk of thromboembolic disease and the combined evidence indicates that mortality from non-breast-cancer causes is not increased by tamoxIFen.
772
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
Jack Cuzick,Mitch Dowsett,Silvia Pineda,C. Wale,Janine Salter,Emma Quinn,Lila Zabaglo,Elizabeth Mallon,Andrew R. Green,Ian O. Ellis,Anthony Howell,Aman U. Buzdar,John F. Forbes +12 more
TL;DR: The amount of prognostic information contained in four widely performed IHC assays is similar to that in the GHI-RS, which confirmed earlier reports that the mRNA-based, 21-gene Genomic Health recurrence score provided additional prognosis information regarding distant recurrence beyond that obtained from classical clinicopathologic factors.
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Joop P. W. van den Bergh,Kathleen I. Pritchard,KS Albain,Stewart J. Anderson,Rodrigo Arriagada,William E. Barlow,W. Bergsten-Nordström,Judith M Bliss,Francesco Boccardo,Rosie Bradley,Marc Buyse,David Cameron,Mike Clarke,M. Coates,Robert E. Coleman,C Correa,J. Costantino,Jack Cuzick,Neville Davidson,C Davies,A. Di Leo,Mitchell Dowsett,Marianne Ewertz,John F. Forbes,R. D. Gelber,R. Geyer,R. Gianni,M. Gnant,A. Goldhirsch,Richard Gray,Daniel F. Hayes,C. Hill,JN Ingle,Wolfgang Janni,Elizabeth MacKinnon,M. Martin,Paul McGale,Larry Norton,Yasuo Ohashi,Soonmyung Paik,Hongchao Pan,E. A. Perez,Richard Peto,R. Piccart,Lori J. Pierce,Vinod Raina,Peter M. Ravdin,J.F.R. Robertson,E.J.T. Rutgers,Joseph A. Sparano,Sandra M. Swain,Carolyn W. Taylor,Giuseppe Viale,G. von Minckwitz,Xiang Wang,Timothy J. Whelan,Nicholas Wilcken,Eric P. Winer,Norman Wolmark,William C. Wood +59 more
TL;DR: In this paper, the authors conducted a collaborative meta-analysis to clarify the risks and benefits of adjuvant bisphosphonate treatment in early breast cancer, and found that the reduction in bone recurrence was more definite (0.73-0.94; 2p=0.004).
676
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy
Andrew W. Bradbury,Andrew W. Bradbury,Donald J. Adam,Jocelyn Bell,John F. Forbes,F. Gerry R. Fowkes,I. Gillespie,C. V. Ruckley,Gillian M. Raab,Basil trial participants +9 more
TL;DR: Overall, there was no significant difference in AFS or OS between the two strategies, however, for those patients who survived for at least 2 years after randomization, a BSX-first revascularization strategy was associated with a significant increase in subsequent OS and a trend towards improved AFS.
570